 Interpace Diagnostics Group, Inc. IDXG announced today that it has closed on a 13 million Convertible Preferred Stock investment by Ampersand Capital Partners Ampersand. This investment constitutes the second tranche of the overall 27 million Convertible Preferred Stock financing provided by Ampersand to Interpace in connection with the Companys July 15, 2019 acquisition of the BioPharma Business of Cancer Genetics, Inc. CGIX. The condition surrounding the second tranche financing was approved by Interpace shareholders which was obtained at the Annual Shareholder Meeting on October 10, 2019. 